GR3025378T3 - Use of monoclonal receptors to oncoproteins for monitoring cancer therapy - Google Patents

Use of monoclonal receptors to oncoproteins for monitoring cancer therapy

Info

Publication number
GR3025378T3
GR3025378T3 GR970403021T GR970403021T GR3025378T3 GR 3025378 T3 GR3025378 T3 GR 3025378T3 GR 970403021 T GR970403021 T GR 970403021T GR 970403021 T GR970403021 T GR 970403021T GR 3025378 T3 GR3025378 T3 GR 3025378T3
Authority
GR
Greece
Prior art keywords
sample
pattern
oncoproteins
cancer therapy
monitoring cancer
Prior art date
Application number
GR970403021T
Other languages
English (en)
Inventor
Henry Lee Niman
Original Assignee
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc
Publication of GR3025378T3 publication Critical patent/GR3025378T3/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GR970403021T 1987-11-09 1997-11-13 Use of monoclonal receptors to oncoproteins for monitoring cancer therapy GR3025378T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11882387A 1987-11-09 1987-11-09

Publications (1)

Publication Number Publication Date
GR3025378T3 true GR3025378T3 (en) 1998-02-27

Family

ID=22380954

Family Applications (1)

Application Number Title Priority Date Filing Date
GR970403021T GR3025378T3 (en) 1987-11-09 1997-11-13 Use of monoclonal receptors to oncoproteins for monitoring cancer therapy

Country Status (10)

Country Link
US (1) US20030215894A1 (el)
EP (1) EP0318179B1 (el)
JP (1) JPH03500928A (el)
AT (1) ATE157172T1 (el)
AU (2) AU2497388A (el)
CA (1) CA1339069C (el)
DE (1) DE3856004T2 (el)
ES (1) ES2108679T3 (el)
GR (1) GR3025378T3 (el)
WO (1) WO1989004489A1 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733738A (en) * 1983-08-17 1998-03-31 Ligand Pharmaceuticals Polypeptide-induced monoclonal receptors to protein ligands
CA1219232A (en) * 1983-08-17 1987-03-17 Richard A. Lerner Polypeptide-induced monoclonal receptors to protein ligands
JP2726264B2 (ja) * 1986-05-06 1998-03-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｎ‐ｍｙｃタンパク質のためのアッセイ及び抗体
ATE160877T1 (de) * 1988-08-12 1997-12-15 Ligand Pharm Inc Polypeptid-induzierte monoklonale rezeptoren gegen proteinliganden
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
US6489451B1 (en) 1997-04-10 2002-12-03 Hefei-Siu-Fung Ustc Pharmaceutical Co., Ltd. Antithrombosis enzyme from the snake venom of agkistrodon acutus
WO1999005161A1 (en) 1997-07-25 1999-02-04 Ligand Pharmaceuticals Incorporated HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
CA2318175A1 (en) * 1998-02-04 1999-08-12 Invitrogen Corporation Microarrays and uses therefor
ATE238555T1 (de) * 1998-02-18 2003-05-15 Theryte Ltd Krebsbehandlung
ES2539830T3 (es) 2006-01-20 2015-07-06 Cell Signaling Technology, Inc. ROS quinasa mutante y de translocación en el carcinoma pulmonar no microcítico humano
US8383799B2 (en) 2006-01-20 2013-02-26 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535058A (en) * 1982-10-01 1985-08-13 Massachusetts Institute Of Technology Characterization of oncogenes and assays based thereon
US4798787A (en) * 1984-09-19 1989-01-17 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
EP0206065A3 (en) * 1985-06-27 1989-04-19 James R. Feramisco Method of detecting oncogene and proto-oncogene related proteins in extracellular biological fluids

Also Published As

Publication number Publication date
AU2967792A (en) 1993-02-11
AU2497388A (en) 1989-05-11
ES2108679T3 (es) 1998-01-01
CA1339069C (en) 1997-07-29
EP0318179A3 (en) 1990-08-01
US20030215894A1 (en) 2003-11-20
EP0318179B1 (en) 1997-08-20
ATE157172T1 (de) 1997-09-15
EP0318179A2 (en) 1989-05-31
DE3856004D1 (de) 1997-09-25
WO1989004489A1 (en) 1989-05-18
DE3856004T2 (de) 1997-12-18
JPH03500928A (ja) 1991-02-28
AU665591B2 (en) 1996-01-11

Similar Documents

Publication Publication Date Title
GR3025378T3 (en) Use of monoclonal receptors to oncoproteins for monitoring cancer therapy
DE69733560D1 (de) TESTVERFAHREN UND REAGENZIEN ZUR QUANTIFIZIERUNG VON hBNP
DK0782709T3 (da) Detektering af cancer
DE68928266D1 (de) Verfahren und vorrichtung zur amperometrischen diagnostischen analyse
ES8303072A1 (es) Metodo para diagnosticar la presencia de una enfermedad especifica, una etapa especifica de una enfermedad, o mas aler- gia, en un paciente, a base de la deteccion de la reacciones antigeno-anticuerpo en un substrato.
ATE76689T1 (de) Verfahren fuer die beschaffung interner referenzen zur verwendung in analyt-rezeptor-tests.
EP1630235A3 (en) Compounds for immunodiagnosis of prostate cancer and method for their use
ATE15229T1 (de) Verfahren zum nachweisen von okkultem humanblut in humanstuhlproben.
ATE123653T1 (de) Vernetzte antikörper und verfahren zu ihrer herstellung.
DE58908905D1 (de) Verfahren zur Bestimmung einer spezifisch bindefähigen Substanz.
ATE107776T1 (de) Verfahren zur bestimmung einer spezifisch bindefähigen substanz.
DE3865678D1 (de) Satz und verfahren zur diagnose der iga-nephropathie.
FR2307270A1 (fr) Procede de determination quantitative d'une substance antigene et ensemble de diagnostic destine a la mise en oeuvre de ce procede
DE69032112T2 (de) Verfahren zur Isolierung von fetalen Zytotrophoblastzellen
DE3485265D1 (de) Verfahren zur bestimmung eines polyvalenten antigens und reagenz hierfuer.
ATE365921T1 (de) Immunologische zusammensetzung zum nachweis von blasenkrebs und verfahren zu ihrer verwendung
DE3587542D1 (de) Verfahren zur Diagnose in vitro von menschlichen Cytomegalovirusinfektionen und Anwendung von monoklonalen Antikörpern gegen Cytomegaloviren, die mit einer cytomegalovirusinduzierten Proteinkinase reagieren.
DE3171892D1 (en) Method for detection of oncofetal antigen, for detection of cancer, for evaluation for cancer therapy and diagnostic kit suitable for such purpose
DE69307707D1 (de) TESTSYSTEM FüR DEGENERATIVE MUSKELERKRANKUNGEN
ATE208041T1 (de) A-protein als diagnostikum für krebs
AU3993089A (en) Enzyme detection wicking assay